Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Ocrevus, Ocrevus 300 mg concentrate for solution for infusion
Hoffmann-La Roche
Multiple Sclerosis (MS)
1 trial -
Octaplex 500 I.E. Pulver und Lösungsmittel zur Herstellung einer Infusionslösung, Octaplex 1000 I.E. Pulver und Lösungsmittel zur Herstellung einer Infusionslösung
Lacuna Pharma Pty Ltd
Acute major bleeding in patients receiving DOAC therapy with factor Xa inhibitor
1 trial -
Odronextamab
Regeneron UK Limited
Follicular Lymphoma (FL)
2 trials -
Odronextamab
Regeneron UK Limited
Diffuse Large B-cell Lymphoma (DLBCL)
1 trial -
Odronextamab
Regeneron UK Limited
Relapsed/Refractory Follicular Lymphoma
1 trial -
Oka strain varicella attenuated live vaccine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Chickenpox Vaccines
1 trial -
Olanzapine
Janssen Cilag International NV
Bipolar Disorder
1 trial -
Olaparib, CISPLATIN , Olaparib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED , CARBOPLATIN
Merck Sharp and Dohme
Stage IV lung cancer condition
1 trial -
Olaparib, ETOPOSIDE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pembrolizumab placebo (saline), Olaparib matching placebo (tablet), CARBOPLATIN , CISPLATIN , Olaparib
Merck Sharp and Dohme
Participants with Limited Stage-Small Cell Lung Cancer, who have received no prior anticancer therapy for their disease.
1 trial -
Olodaterol (BI 1744)
Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
2 trials -
Olokizumab
International Peace Maternity and Child Health Hospital
Rheumatoid Arthritis
1 trial -
Olokizumab 64 mg SC q4w
International Peace Maternity and Child Health Hospital
Rheumatoid Arthritis
1 trial -
Olokizumab 64mg q4w
International Peace Maternity and Child Health Hospital
Rheumatoid Arthritis
1 trial -
Olorofim
Biotech Pharmaceutical Co.,
Invasive Aspergillosis
1 trial -
Olumiant 4 mg film-coated tablets, Placebo of Olumiant 4mg
Pari Pharma GmbH
Dermatomyositis; Baricitinib in patients with relapsing or naïve dermatomyositis.
1 trial -
Omecamtiv Mecarbil, Omecamtiv Mecarbil, Matching Placebo, Omecamtiv Mecarbil
Cytokinetics (Ireland) Limited
Heart Failure With Reduced Ejection Fraction
1 trial -
Omicron COVID-19 Vaccine (Vero Cell), Inactivated
Xiyuan Hospital of China Academy of Chinese Medical Sciences
COVID-19
2 trials -
Omvoh 300 mg concentrate for solution for infusion, Omvoh 100 mg solution for injection in pre-filled syringe
Eli Lilly Co.
Moderately to Severely Active Ulcerative Colitis
1 trial -
On-site bundled rapid HIV/HCV testing
BRIGHT MINDS BIOSCIENCES INC.
Substance-related Disorders
1 trial -
Ondansetron
United Therapeutics Europe Ltd
IBS - Irritable Bowel Syndrome
1 trial -
Ondansetron Aurobindo 8 mg Filmtabletten, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Dexametazona Krka 4 mg comprimate, EMEND 125 mg+80 mg hard capsules, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, G
Karyopharm Therapeutics Inc
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
1 trial -
Onpattro 2 mg/mL concentrate for solution for infusion., Sodium Chloride Intravenous Infusion BP 0.9% w/v
Alnylam Netherlands B.V.
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)
1 trial -
Open Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alpha (PRX-102) 2 mg/kg Administered by Intravenous Infusion Every 4 Weeks in Patients with Fabry Disease
Chiesi Farmaceutici S.p.A
Fabry disease (α-galactosidase A deficiency)
1 trial -
Open Label Topical Beremagene Geperpavec (B-VEC)
Krystal Biotech Netherlands B.V.
Dystrophic Epidermolysis Bullosa
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources